3. Bernard-Marty C, Cardoso F, Piccart MJ. Facts and controversies in systemic treatment of metastatic breast cancer. Oncologist 2004;9:617-32.
4. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006;24:2137-50.
5. Esteva FJ, Valero V, Pusztai L, Boehnke-Michaud L, Buzdar AU, Hortobagyi GN. Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond. Oncologist 2001;6:133-46.
6. Pronzato P, Rondini M. First line chemotherapy of metastatic breast cancer. Ann Oncol 2006;17 Suppl 5:v165-8.
7. Decatris MP, Sundar S, O’Byrne KJ. Platinum-based chemotherapy in metastatic breast cancer: the Leicester (U.K.) experience. Clin Oncol (R Coll Radiol) 2005;17:249-5.
8. Crown J, Diéras V, Kaufmann M, von Minckwitz, Kaye S, Leonard R, et al. Chemotherapy for metastatic breast cancer: report of a European expert panel. Lancet Oncol 2002;3:719-27.
9. Cocconi G, Bisagni G, Bacchi M, Boni C, Bartolucci R, Ceci G, et al. Cisplatin and etoposide as first-line chemotherapy for metastatic breast carcinoma: a prospective randomized trial of the Italian Oncology Group for Clinical Research. J Clin Oncol 1991;9:664-9.
10. Go RS, Adjei AA. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 1999;17:409-22.
11. Roché H, Vahdat LT. Treatment of metastatic breast cancer: second line and beyond. Ann Oncol 2011;22:1000-10.
12. Gordaliza M, García PA, del Corral, Castro MA, Gómez-Zurita MA. Podophyllotoxin: distribution, sources, applications and new cytotoxic derivatives. Toxicon 2004;44:441-59.
13. Decatris MP, Sundar S, O’Byrne KJ. Platinum-based chemotherapy in metastatic breast cancer: current status. Cancer Treat Rev 2004;30:53-81.
14. Cocconi G, Tonato M, Di Costanzo, Bisagni G, Belsanti V, Buzzi F, et al. Platinum and etoposide in chemotherapy refractory metastatic breast cancer: a phase II trial of the Italian Oncology Group for Clinical Research (G.O.I.R.C.). Eur J Cancer Clin Oncol 1986;22:761-4.
15. Durand RE, Goldie JH. Interaction of etoposide and cisplatin in an in vitro tumor model. Cancer Treat Rep 1987;71:673-9.
16. Lluch A, Azagra P, Cervantes A, Muñoz M, Alberola V, Santabarbara P, et al. Phase II trial of cisplatin and etoposide as first-line therapy in metastatic breast carcinoma. Oncology 1994;51:352-5.
17. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
18. Howlader N, Chen VW, Ries LA, Loch MM, Lee R, DeSantis C, et al. Overview of breast cancer collaborative stage data items: their definitions, quality, usage, and clinical implications: a review of SEER data for 2004-2010. Cancer 2014;120 Suppl 23:3771-80.
19. Fried G, Stein ME, Haim N. Clinical activity of cisplatin and prolonged oral administration of etoposide in previously treated, anthracycline-resistant, metastatic breast cancer patients: a phase II study. Med Pediatr Oncol 2000;34:10-3.
20. Franciosi V, Cocconi G, Michiara M, Di Costanzo, Fosser V, Tonato M, et al. Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study. Cancer 1999;85:1599-605.
21. Martín M. Platinum compounds in the treatment of advanced breast cancer. Clin Breast Cancer 2001;2:190-208.